Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors.

October 16, 2015, 6:16 am

≫ Next: Plant derived substances with anti-cancer activity: from folklore to practice.

≪ Previous: Evaluation of cannabinoid CB1 and CB2 receptors expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients’ survival.

$

0

0

“Macrophages are pivotal effector cells in immune responses and tissue remodeling by producing a wide spectrum of mediators, including angiogenic and lymphangiogenic factors.

Activation of cannabinoid receptor types 1 and 2 has been suggested as a new strategy to modulate angiogenesis in vitro and in vivo.

We investigated whether human lung-resident macrophages express a complete endocannabinoid system by assessing their production of endocannabinoids and expression of cannabinoid receptors…

Activation of cannabinoid receptors on tissue-resident macrophages might be a novel strategy to modulate macrophage-assisted vascular remodeling in cancer and chronic inflammation.”

http://www.ncbi.nlm.nih.gov/pubmed/26467187

---

Plant derived substances with anti-cancer activity: from folklore to practice.

October 21, 2015, 4:05 am

≫ Next: Cannabinoids and cancer: potential for colorectal cancer therapy.

≪ Previous: Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors.

$

0

0

“Plants have had an essential role in the folklore of ancient cultures. In addition to the use as food and spices, plants have also been utilized as medicines for over 5000 years.

It is estimated that 70-95% of the population in developing countries continues to use traditional medicines even today. A new trend, that involved the isolation of plant active compounds begun during the early nineteenth century.

This trend led to the discovery of different active compounds that are derived from plants.

In the last decades, more and more new materials derived from plants have been authorized and subscribed as medicines, including those with anti-cancer activity.

Cancer is among the leading causes of morbidity and mortality worldwide. The number of new cases is expected to rise by about 70% over the next two decades. Thus, there is a real need for new efficient anti-cancer drugs with reduced side effects, and plants are a promising source for such entities.

Here we focus on some plant-derived substances exhibiting anti-cancer and chemoprevention activity, their mode of action and bioavailability. These include paclitaxel, curcumin, and cannabinoids.

In addition, development and use of their synthetic analogs, and those of strigolactones, are discussed. Also discussed are commercial considerations and future prospects for development of plant derived substances with anti-cancer activity.”

http://www.ncbi.nlm.nih.gov/pubmed/26483815

Cannabinoids and cancer: potential for colorectal cancer therapy.

October 23, 2015, 7:21 am

≫ Next: Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions.

≪ Previous: Plant derived substances with anti-cancer activity: from folklore to practice.

$

0

0

“Despite extensive research into the biology of CRC (colorectal cancer), and recent advances in surgical techniques and chemotherapy, CRC continues to be a major cause of death throughout the world. Therefore it is important to develop novel chemopreventive/chemotherapeutic agents for CRC.

Cannabinoids are a class of compounds that are currently used in the treatment of chemotherapy-induced nausea and vomiting, and in the stimulation of appetite. However, there is accumulating evidence that they could also be useful for the inhibition of tumour cell growth by modulating key survival signalling pathways.

The chemotherapeutic potential for plant-derived and endogenous cannabinoids in CRC therapy is reviewed.”

http://www.ncbi.nlm.nih.gov/pubmed/16042581

Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions.

November 6, 2015, 2:35 am

≫ Next: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.

≪ Previous: Cannabinoids and cancer: potential for colorectal cancer therapy.

$

0

0

“The endocannabinoid system is comprised of cannabinoid receptors (CB1 and CB2), their endogenous ligands (endocannabinoids), and proteins responsible for their metabolism participate in many different functions indispensable to homeostatic regulation in several tissues, exerting also antitumorigenic effects.

The present study aimed to evaluate the clinical significance of CB1 and CB2 expression in human benign and malignant thyroid lesions.

Our data suggest that CB receptors may be involved in malignant thyroid transformation and especially CB2 receptor could serve as useful biomarker and potential therapeutic target in thyroid neoplasia.”

http://www.ncbi.nlm.nih.gov/pubmed/26539529

http://www.hindawi.com/journals/bmri/2015/839403/

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.

November 13, 2015, 5:51 am

≫ Next: Controlled release tablet formulation containing natural δ9 tetrahydrocannabinol.

≪ Previous: Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions.

$

0

0

“Cannabis has a long history of medicinal use.

Cannabis-based medications (cannabinoids) are based on its active element, delta-9-tetrahydrocannabinol (THC), and have been approved for medical purposes.

Cannabinoids may be a useful therapeutic option for people with chemotherapy-induced nausea and vomiting that respond poorly to commonly used anti-emetic agents (anti-sickness drugs).

Cannabis-based medications may be useful for treating refractory chemotherapy-induced nausea and vomiting.”

http://www.ncbi.nlm.nih.gov/pubmed/26561338

http://www.thctotalhealthcare.com/category/nauseavomiting/

Controlled release tablet formulation containing natural δ9 tetrahydrocannabinol.

November 21, 2015, 2:57 am

≫ Next: Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2

≪ Previous: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.

$

0

0

“Cannabinoids are increasingly being used in the treatment of chemotherapy induced nausea and vomiting (CINV) because of their action on the cannabinoid receptors, CB1 and CB2.

The currently marketed capsule formulations (sesame oil based and crystalline powder) are required to be administered frequently to maintain therapeutic levels, which leads to non-compliance.

In the present study, oral controlled release tablet formulations of Δ9- tetrahydrocannabinol (THC) were prepared using the lipids Precirol® and Compritrol®. Release profiles using THC-lipid matrices and/or with the lipids in the external phase (blend) were evaluated…

The overall results demonstrate the feasibility of preparing oral THC tablets for once a day administration which can improve CINV management.”

http://www.ncbi.nlm.nih.gov/pubmed/26585693

Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2

December 3, 2015, 1:32 pm

≫ Next: The therapeutic aspects of the endocannabinoid system (ECS) for cancer and their development: from nature to laboratory.

≪ Previous: Controlled release tablet formulation containing natural δ9 tetrahydrocannabinol.

$

0

0

“Osteosarcoma is the most frequent primary malignant bone tumor that occurs in children and adolescents. Osteosarcoma is a bone malignancy that predominantly affects children and adolescents, and exhibits high invasion and metastasis rates.

Although adriamycin (ADM) is an effective benchmark agent for the management of osteosarcoma, it also results in harmful side-effects including toxicity and chemoresistance that substantially affect the quality of life of patients. Therefore, novel therapeutic approaches and drugs must be sought for the treatment of osteosarcoma.

Natural products which have potential antitumor activities have become a focus of attention for study in previous years. Cannabinoids, the active components naturally derived from the marijuana plant Cannabis sativa L., have been reported as potential antitumor drugs based on their ability to limit inflammation, cell proliferation and cell survival.

To date, several cannabinoids have been identified and characterized, including Δ(9)-tetrahydrocannabinol (THC), cannabidiol, cannabinol (CBN) and anandamide, as well as synthetic cannabinoids, including WIN-55,212-2, JWH-133 and (R)-methanandamide.

In the early 1970s, THC and CBN were shown to inhibit tumor growth in Lewis lung carcinoma. Subsequently, cannabinoids were found to induce apoptosis and inhibit the proliferation of various cancer cells, including those of glioma and lymphoma, and prostate, breast, skin and pancreatic cancer…

In conclusion, the present study indicated that cannabinoid WIN-55,212-2 is antiproliferative, antimetastatic and antiangiogenic against MG-63 cells in vitro, and presented evidence that cannabinoid WIN-55,212-2 may result in synergistic antitumor action in combination with ADM against osteosarcoma.

These findings may offer a novel strategy for the treatment of osteosarcoma.”

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580018/

The therapeutic aspects of the endocannabinoid system (ECS) for cancer and their development: from nature to laboratory.

December 15, 2015, 11:42 am

≫ Next: Cannabis ‘Can Reduce Tumour Growth’, Expert Says

≪ Previous: Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2

$

0

0

“The endocannabinoid system (ECS) is a group of neuromodulatory lipids and their receptors, which are widely distributed in mammalian tissues. ECS regulates various cardiovascular, nervous, and immune system functions inside cells.

In recent years, there has been a growing body of evidence for the use of synthetic and natural cannabinoids as potential anticancer agents.

For instance, the CB1 and CB2 receptors are assumed to play an important role inside the endocannabinoid system. These receptors are abundantly expressed in the brain and fatty tissue of the human body.

Despite recent developments in molecular biology, there is still a lack of knowledge about the distribution of CB1 and CB2 receptors in the human kidney and their role in kidney cancer. To address this gap, we explore and demonstrate the role of the endocannabinoid system in renal cell carcinoma (RCC).

In this brief overview, we elucidate the therapeutic aspects of the endocannabinoid system for various cancers and explain how this system can be used for treating kidney cancer.

Overall, this review provides new insights into cannabinoids’ mechanisms of action in both in vivo and in vitro models, and focuses on recent discoveries in the field.”

 http://www.ncbi.nlm.nih.gov/pubmed/26654588

---

Cannabis ‘Can Reduce Tumour Growth’, Expert Says

December 15, 2015, 1:34 pm

≫ Next: Anti Proliferative and Pro Apoptotic Effects of Flavonoid Quercetin Are Mediated by CB1 Receptor in Human Colon Cancer Cell Lines.

≪ Previous: The therapeutic aspects of the endocannabinoid system (ECS) for cancer and their development: from nature to laboratory.

$

0

0

“He believes chemicals in cannabis could be anti-cancer agents”

“Marijuana is now used by cancer patients in some countries to ease the pain of their illness – but it might actually offer a cure.Guillermo Velasco of the Complutense University of Madrid says there is evidence that cannabinoids – chemicals in cannabis – actually reduced tumour growth in animals.But he says that there is little interest from pharmaceutical companies.

Velasco told Upworthy,, ‘One of the reasons why [it] is so complicated to promote clinical studies is that the active components of marijuana are natural products that cannot be patented and therefore there are few pharma companies interested in their clinical development.’

Earlier this year, the U.S. government admitted that the drug can shrink cancer cells in rodent studies.

In a page of official government advice, the U.S. government now says,, ‘Cannabis has been shown to kill cancer cells in the laboratory.’

The site says that the effect has so far been seen in rodent studies, and cautions,  ‘At this time, there is not enough evidence to recommend that patients inhale or ingest Cannabis as a treatment for cancer-related symptoms or side effects of cancer therapy.’’”  https://uk.news.yahoo.com/cannabis–can-reduce-tumour-growth—expert-says-120408138.html#pQEf8NO

http://www.thctotalhealthcare.com/category/cancer/

Anti Proliferative and Pro Apoptotic Effects of Flavonoid Quercetin Are Mediated by CB1 Receptor in Human Colon Cancer Cell Lines.

January 5, 2016, 10:00 am

≫ Next: Ligands for cannabinoid receptors, promising anticancer agents.

≪ Previous: Cannabis ‘Can Reduce Tumour Growth’, Expert Says

$

0

0

“Quercetin, the major constituent of flavonoid and widely present in fruits and vegetables, is an attractive compound for cancer prevention due to its beneficial anti proliferative effects, showing a crucial role in the regulation of apoptosis and cell cycle signaling.

In vitro studies have demonstrated that quercetin specifically influences colon cancer cell proliferation.

Our experiments, using human colon adenocarcinoma cells, confirmed the anti proliferative effect of quercetin and gave intriguing new insight in to the knowledge of the mechanisms involved…

These findings open new perspectives for anticancer therapeutic strategies.”

http://www.ncbi.nlm.nih.gov/pubmed/25893829

“Flavonoid glycosides and cannabinoids from the pollen of Cannabis sativa L.”  http://www.ncbi.nlm.nih.gov/pubmed/15688956

Ligands for cannabinoid receptors, promising anticancer agents.

January 15, 2016, 3:29 am

≫ Next: Cannabinoids inhibit cellular respiration of human oral cancer cells.

≪ Previous: Anti Proliferative and Pro Apoptotic Effects of Flavonoid Quercetin Are Mediated by CB1 Receptor in Human Colon Cancer Cell Lines.

$

0

0

“Cannabinoids compounds are unique to cannabis and provide some interesting biological properties.

These compounds along with endocannabinoids, a group of neuromodulator compounds in the body especially in brain, express their effects by activation of G-protein-coupled cannabinoid receptors, CB1 and CB2.

There are several physiological properties attributed to the endocannabinoids including pain relief, enhancement of appetite, blood pressure lowering during shock, embryonic development, and blocking of working memory.

On the other hand, activation of endocannabinoid system may be suppresses evolution and progression of several types of cancer.

According to the results of recent studies, CB receptors are over-expressed in cancer cell lines and application of multiple cannabinoid or cannabis-derived compounds reduce tumor size through decrease of cell proliferation or induction of cell cycle arrest and apoptosis along with desirable effect on decrease of tumor-evoked pain.

Therefore, modulation of endocannabinoid system by inhibition of fatty acid amide hydrolase (FAAH), the enzyme, which metabolized endocannabinoids, or application of multiple cannabinoid or cannabis-derived compounds, may be appropriate for the treatment of several cancer subtypes. This review focuses on how cannabinoid affect different types of cancers.”

http://www.ncbi.nlm.nih.gov/pubmed/26764235

http://www.thctotalhealthcare.com/category/cancer/

Cannabinoids inhibit cellular respiration of human oral cancer cells.

January 15, 2016, 6:04 am

≫ Next: Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns

≪ Previous: Ligands for cannabinoid receptors, promising anticancer agents.

$

0

0

“The primary cannabinoids, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and Delta(8)-tetrahydrocannabinol (Delta(8)-THC) are known to disturb the mitochondrial function and possess antitumor activities.

These observations prompted us to investigate their effects on the mitochondrial O(2) consumption in human oral cancer cells (Tu183). This epithelial cell line overexpresses bcl-2 and is highly resistant to anticancer drugs.

A rapid decline in the rate of respiration was observed when Delta(9)-THC or Delta(8)-THC was added to the cells. The inhibition was concentration-dependent, and Delta(9)-THC was the more potent of the two compounds.

 

Anandamide (an endocannabinoid) was ineffective; suggesting the effects of Delta(9)-THC and Delta(8)-THC were not mediated by the cannabinoid receptors.

These results show the cannabinoids are potent inhibitors of human oral cancer cells (Tu183) cellular respiration and are toxic to this highly malignant tumor.”

http://www.ncbi.nlm.nih.gov/pubmed/20516734

http://www.thctotalhealthcare.com/category/oral-cancer/

Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns

January 18, 2016, 5:27 pm

≫ Next: Granite City Man Claims Cannabis Oil Cured His ‘Incurable’ Cancer

≪ Previous: Cannabinoids inhibit cellular respiration of human oral cancer cells.

$

0

0

“It has been previously demonstrated in several cancer models, that Dronabinol (THC) may have anti-tumor activity – however, controversial data exists for acute leukemia. We have anecdotal evidence that THC may have contributed to disease control in a patient with acute undifferentiated leukemia.

To test this hypothesis, we evaluated the antileukemic efficacy of THC in several leukemia cell lines and native leukemia blasts cultured ex vivo.

We here reveal a novel aspect of dronabinol, a cannabinoid derivative, which displays remarkable antiproliferative as well as proapoptotic efficacy in a distinct leukemia patient cohort – in vitro and in ex vivo native leukemia blasts. It has been previously reported that cannabinoids display anticancer properties. However, due to legal issues the use and exploration of such agents is highly limited in many countries.

Importantly, we demonstrate that antileukemic concentrations are achievable in vivo.

Our study provides rigorous data to support clinical evaluation of THC as a low-toxic therapy option in a well defined subset of acute leukemia patients.”

http://www.ncbi.nlm.nih.gov/pubmed/26775260

http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-2029-8

Granite City Man Claims Cannabis Oil Cured His ‘Incurable’ Cancer

January 26, 2016, 8:16 am

≫ Next: Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveal a Mechanism for Regulation of Tumor Progression.

≪ Previous: Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns

$

0

0

“Darren Miller is ready to enjoy his second chance at life.

The 50-year-old Granite City man is putting out the word that a steady diet of cannabis oil coupled with chemotherapy wiped out what doctors had only months earlier diagnosed as “incurable, inoperable” lung and pericardial heart sac cancer.

He’d basically been given about a year to live, with chemo.

“Glad to be here, glad to be anywhere with the diagnosis I had,” Miller said by way of introduction during a sitdown with KMOX News.

He carried with him a stack of medical documents to back his claim that he’s been given a clean bill of health just months after being handed a death sentence.

“I have the medical records to show the evidence of what I’m saying,” Miller said. “Now it’s going to be interpreted differently by people everywhere, but I’ve researched and there are thousands of testimonies that you can go on the internet and see every day people doing this and it’s been going on for years.””

http://stlouis.cbslocal.com/2016/01/22/granite-city-man-claims-cannabis-oil-killed-his-incurable-cancer/

“Granite City Man Claims Cannabis Oil Killed His “Incurable” Cancer”  http://stlouis.suntimes.com/stl-news/7/139/238717/granite-city-man-claims-cannabis-oil-killed-his-incurable-cancer

Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveal a Mechanism for Regulation of Tumor Progression.

February 5, 2016, 4:48 am

≫ Next: Medicinal cannabis.

≪ Previous: Granite City Man Claims Cannabis Oil Cured His ‘Incurable’ Cancer

$

0

0

“The G-protein-coupled chemokine receptor, CXCR4, generates signals that lead to cell migration, cell proliferation, and other survival mechanisms which result in the metastatic spread of primary tumor cells to distal organs.

Numerous studies have demonstrated that CXCR4 can form homodimers, or can heterodimerize with other GPCRs to form receptor complexes that can amplify or decrease the signaling capacity of each individual receptor.

Using biophysical and biochemical approaches, we found that CXCR4 can form an induced heterodimer with cannabinoid receptor 2 (CB2) in human breast and prostate cancer cells.

Simultaneous, agonist-dependent activation of CXCR4 and CB2 resulted in reduced CXCR4-mediated expression of phosphorylated ERK1/2, and ultimately, reduced cancer cell functions such as calcium mobilization and cellular chemotaxis.

Given that treatment with cannabinoids has been shown to reduce invasiveness of cancer cells, as well as CXCR4-mediated migration of immune cells, it is therefore plausible that CXCR4 signaling can be silenced through a physical heterodimeric association with CB2, thereby inhibiting subsequent functions of CXCR4.

Taken together, the data illustrates a mechanism by which the cannabinoid system can negatively modulate CXCR4 receptor function, and perhaps, tumor progression.”

http://www.ncbi.nlm.nih.gov/pubmed/26841863

---

Medicinal cannabis.

February 5, 2016, 5:07 am

≫ Next: Cannabinoid pharmacology in cancer research: A new hope for cancer patients?

≪ Previous: Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveal a Mechanism for Regulation of Tumor Progression.

$

0

0

“A number of therapeutic uses of cannabis and its derivatives have been postulated from preclinical investigations.

Possible clinical indications include spasticity and pain in multiple sclerosis, cancer-associated nausea and vomiting, cancer pain and HIV neuropathy.

Controversies lie in how to produce, supply and administer cannabinoid products.

Introduction of cannabinoids therapeutically should be supported by a regulatory and educational framework that minimises the risk of harm to patients and the community.

The Regulator of Medicinal Cannabis Bill 2014 is under consideration in Australia to address this.

Nabiximols is the only cannabinoid on the Australian Register of Therapeutic Goods at present, although cannabidiol has been recommended for inclusion in Schedule 4.”

http://www.ncbi.nlm.nih.gov/pubmed/26843715

“There is some evidence of therapeutic benefit for cannabis products in defined patient populations.” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674028/

Cannabinoid pharmacology in cancer research: A new hope for cancer patients?

February 9, 2016, 6:40 am

≫ Next: Smoking marijuana reduces cancer risk

≪ Previous: Medicinal cannabis.

$

0

0

“Cannabinoids have been used for many centuries to ease pain and in the past decade, the endocannabinoid system has been implicated in a number of pathophysiological conditions, such as mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis, spinal cord injury, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity, and osteoporosis.

Several studies have demonstrated that cannabinoids also have anti-cancer activity and as cannabinoids are usually well tolerated and do not produce the typical toxic effects of conventional chemotherapies, there is considerable merit in the development of cannabinoids as potential anticancer therapies.

Whilst the presence of psychoactive effects of cannabinoids could prevent any progress in this field, recent studies have shown the value of the non-psychoactive components of cannabinoids in activating apoptotic pathways, inducing anti-proliferative and anti-angiogenic effects.

The aforementioned effects are suggested to be through pathways such as ERK, Akt, mitogen-activated protein kinase (MAPK) pathways, phosphoinositide 3-kinase (PI3K) pathways and hypoxia inducible factor 1 (HIF1), all of which are important contributors to the hallmarks of cancer.

Many important questions still remain unanswered or are poorly addressed thus necessitating further research at basic pre-clinical and clinical levels. In this review, we address these issues with a view to identifying the key challenges that future research needs to address.”

http://www.ncbi.nlm.nih.gov/pubmed/26852955

http://www.thctotalhealthcare.com/category/cancer/

Smoking marijuana reduces cancer risk

February 16, 2016, 6:35 am

≫ Next: Endocannabinoids as Guardians of Metastasis.

≪ Previous: Cannabinoid pharmacology in cancer research: A new hope for cancer patients?

$

0

0

“Marijuana reduces cancer risk and kills existing tumors”

“This may be hard to believe — as we’re fairly accustomed to the notion that inhaling smoke is always bad for your health — but research shows smoking marijuana actually decreases the risk for developing lung cancer.

According to multiple study findings published on Cancer.gov, “Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death.”

Dr. Donald Tashkin, professor emeritus of medicine at UCLA, also recently revealed to LA Weekly that after 30 years of studying the effects of marijuana smoke on lung function, he did not find any association between lung cancer and smoking weed.

Smoking marijuana doesn’t lead to impaired lung function either

Tashkin also found smoking marijuana does not lead to impaired lung function even after years of habitual use.”

More: http://extract.suntimes.com/information-resources/10/153/892/smoking-marijuana-reduces-cancer-risk

“Cannabis has been shown to kill cancer cells in the laboratory. Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death.” http://www.cancer.gov/about-cancer/treatment/cam/patient/cannabis-pdq#section/all

http://www.thctotalhealthcare.com/category/cancer/

Endocannabinoids as Guardians of Metastasis.

February 16, 2016, 4:43 pm

≫ Next: Natural product modulators of transient receptor potential (TRP) channels as potential anti-cancer agents.

≪ Previous: Smoking marijuana reduces cancer risk

$

0

0

“Endocannabinoids including anandamide and 2-arachidonoylglycerol are involved in cancer pathophysiology in several ways, including tumor growth and progression, peritumoral inflammation, nausea and cancer pain.

Recently we showed that the endocannabinoid profiles are deranged during cancer to an extent that this manifests in alterations of plasma endocannabinoids in cancer patients, which was mimicked by similar changes in rodent models of local and metastatic cancer.

The present topical review summarizes the complexity of endocannabinoid signaling in the context of tumor growth and metastasis.”

http://www.ncbi.nlm.nih.gov/pubmed/26875980

Natural product modulators of transient receptor potential (TRP) channels as potential anti-cancer agents.

February 19, 2016, 4:50 am

≫ Next: Cannabinoids: Medical implications.

≪ Previous: Endocannabinoids as Guardians of Metastasis.

$

0

0

“Treatment of cancer is a significant challenge in clinical medicine, and its research is a top priority in chemical biology and drug discovery. Consequently, there is an urgent need for identifying innovative chemotypes capable of modulating unexploited drug targets.

The transient receptor potential (TRPs) channels persist scarcely explored as targets, despite intervening in a plethora of pathophysiological events in numerous diseases, including cancer.

Both agonists and antagonists have proven capable of evoking phenotype changes leading to either cell death or reduced cell migration.

Among these, natural products entail biologically pre-validated and privileged architectures for TRP recognition.

Furthermore, several natural products have significantly contributed to our current knowledge on TRP biology. In this Tutorial Review we focus on selected natural products, e.g. capsaicinoids, cannabinoids and terpenes, by highlighting challenges and opportunities in their use as starting points for designing natural product-inspired TRP channel modulators.

Importantly, the de-orphanization of natural products as TRP channel ligands may leverage their exploration as viable strategy for developing anticancer therapies.

Finally, we foresee that TRP channels may be explored for the selective pharmacodelivery of cytotoxic payloads to diseased tissues, providing an innovative platform in chemical biology and molecular medicine.”

http://www.ncbi.nlm.nih.gov/pubmed/26890476

http://www.thctotalhealthcare.com/category/cancer/